Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

OrthoGrid announces a new clinical whitepaper for review. A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

OrthoGrid announces a new clinical whitepaper for review.

A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented by either the HipGrid®Drone™ (Drone) or PhantomMSK® Hip (Phantom) (OrthoGrid Systems Inc.

, Salt Lake City, UT, USA) to assist in the positioning of total hip arthroplasty components including cementless, short femoral stem and acetabular cup. The pre-defined target leg length discrepancy (LLD) and global hip offset (GHO) was less than 10mm and acetabular cup abduction angle (ABD) target was 45 degrees plus or minus 10 degrees for the Drone and 42 degrees plus or minus 10 degrees for the Phantom. Accuracy of component placement was evaluated on the six-week post-operative, weight bearing radiographs.

Fluoroscopy times were recorded directly from the c-arm imaging device and surgical times were defined as incision to wound closure. Percentages of patients achieving each component placement goal, as well as reaching all three accuracy goals, were also evaluated. Continuous variables were non-parametric, therefore, group differences were determined by the Mann-Whitney U test and categorical data were evaluated with the Fisher Exact test.

Click here to download the whitepaper:

Some of the data in this whitepaper were previously published in the Journal of Arthroplasty (DOI: 10/1016/j.arth.2020.06.053) by senior surgeon Dr. Cass Nakasone of Straub Medical Center, Bone and Joint Center, Honolulu, HI 96813. Click here to view the article on arthroplastyjournal.org.

To request a HipGrid Drone product demo or a PhantomMSK Hip software demo, please click here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS's ACCESS payment model, fully active as of July 2026, pays companies $90 to $420 per Medicare beneficiary per year for technology-supported chronic care tied to outcomes, according to HFMA. The model also requires participants to connect through CMS-designated interoperability networks, and more tech companies than traditional providers have signed on so far.

  • 01CMS ACCESS model provides annual payments of $90 to $420 per Medicare beneficiary for chronic care supported by technology.
  • 02Payments in the ACCESS model range from $90 to $420 per beneficiary per year depending on whether specified outcome targets are met.
  • 03The initiative aims to promote the integration of technology in chronic care management.

Sep 10, 2026

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI says roughly 10,000 AI agents produced a proposed Navier–Stokes solution in 88 hours, followed by Lean verification. For healthcare and life sciences, the immediate signal is a research workflow built around parallel agents, code execution, provenance and formal checking—not a ready-made clinical simulator.

  • 01OpenAI's result is a proposed proof under review, not a new clinical simulation product.
  • 02The near-term B2B signal is a coordinated research stack combining agents, code and formal verification.
  • 03Healthcare buyers should evaluate provenance, reproducibility, security and cost per validated result.

Sep 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512